CSS
OBIO icon

Cubist Systematic Strategies’s Orchestra BioMed OBIO Stock Holding History

Cubist Systematic Strategies’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$193K Buy
77,892
+60,176
+340% +$166K ﹤0.01% 2665
2025
Q2 		$47.5K Buy
+17,716
New +$51.7K ﹤0.01% 2786

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cubist Systematic Strategies's OBIO Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Orchestra BioMed (OBIO) stake by 340% in Q3 2025, buying an estimated $166K and bringing the position to 77,892 shares worth $193K. The position accounts for ﹤0.01% of the portfolio, ranked #2665.

Cubist Systematic Strategies first reported a position in OBIO in Q2 2025 and has held it in 2 quarters since. 52 funds tracked by Wall St. Rank hold OBIO as of Q3 2025.

  • Cubist Systematic Strategies held 77,892 shares of Orchestra BioMed worth $193K as of Q3 2025.
  • Cubist Systematic Strategies bought 60,176 Orchestra BioMed shares in Q3 2025, an estimated $166K.
  • Orchestra BioMed made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2665 holding.
  • Cubist Systematic Strategies first reported a position in Orchestra BioMed in Q2 2025 and has held it in 2 quarters since.
  • 52 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.